New
HealthMore in Health →
A KRAS Drug Candidate Is Raising Hopes for Pancreatic Cancer Treatment
A pancreatic cancer drug candidate from Revolution Medicines, daraxonrasib, is being described as one of the most promising developments in decades, with early signs of unusually strong results against a target long seen
Key Takeaways
- A Revolution Medicines drug candidate is being described as one of the most promising pancreatic cancer advances in decades.
- The therapy targets KRAS, a long-frustrating protein in cancer drug development.
DE
DT Editorial AI··via statnews.com